DV
Dividend Vision

ELUT — Elutia Inc.

Elutia Inc. (ELUT)

Total return is -93.5% over the past 5.8 years, 237.7 points behind SPY at 144.2%. Its deepest 1-year drawdown was 79.0%.

Elutia Inc. is a commercial-stage biopharmaceutical company developing drug-eluting biomatrix products for surgical reconstruction applications, with a focus on women's health and cardiovascular repair. The company markets several products including SimpliDerm for soft tissue reconstruction, ProxiCor for cardiac tissue repair, Tyke for neonatal and infant cardiac applications, and VasCure for vascular reconstruction, selling directly to hospitals and healthcare facilities through independent sales agents. The company does not currently distribute dividends.

ELUT key facts

Asset type
Stock
Asset class
Equity
Inception date
10/08/2020
Last close
$0.94
Market cap
$41,997,824
Average volume
71125.0
Beta
0.85
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.65